MarketCapExport financials
NeoGenomics (NEO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
NeoGenomics Income Statement 2025-2009 | NEO
Brief overview of profit and loss at NeoGenomics
This overview is based on financial performance over the past five years. Revenue reported by NeoGenomics was 444 million dollars at the beginning of the period and 727 million dollars at the end. The total change was +63.6%, with a CAGR of approximately 10.4%. Top-line growth remained consistently strong over the period.
Gross profit changed from $186 million to $314 million (+69.1%). The relationship between revenue and direct costs remained stable. Gross margin moved from 41.8% to 43.2%. The gross margin stayed within a similar range.
Over the period, EBITDA shifted from $11.9 million to −$79.8 million, a change of −770%. EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from 2.7% to −11%. Operating return per unit of revenue declined.
The final result was 4.2 million dollars initially and −108 million dollars in the final year. The business lost profitability by the end of the period.
Market capitalization changed from 5.5 billion dollars to 1.5 billion dollars (−73.2%). Capitalization lags the underlying business improvement.
Summary assessment
Signs of deterioration dominate the five-year picture. The positive side is supported by a stronger gross margin and a larger revenue base. The weaker side of the profile includes a weaker final result, limited operating profitability and weaker operating efficiency. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement NeoGenomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.48 B | 1.53 B | 1.84 B | 1.96 B | 2.57 B | 5.53 B | 3.33 B | 1.42 B | 616 M | 627 M | 413 M | 216 M | 208 M | 128 M | 75.3 M | 52.4 M | - |
Shares |
128 M | 127 M | 126 M | 124 M | 120 M | 109 M | 100 M | 85.6 M | 79.4 M | 77.5 M | 60.5 M | 53.5 M | 48.3 M | 45 M | 42.8 M | 37.4 M | - |
Historical Prices |
11.6 | 12.1 | 14.7 | 15.8 | 21.4 | 51 | 28.3 | 19.6 | 8.4 | 8.07 | 6.37 | 4.54 | 3.58 | 3.34 | 1.67 | 1.4 | 1.32 |
Net Income |
-108 M | -79 M | -88 M | -144 M | -8.35 M | 4.17 M | 8.01 M | 2.64 M | -846 K | -5.72 M | -2.54 M | 1.13 M | 2.03 M | 65 K | -1.18 M | -3.3 M | - |
Revenue |
727 M | 661 M | 592 M | 510 M | 484 M | 444 M | 409 M | 277 M | 259 M | 244 M | 99.8 M | 87.1 M | 66.5 M | 59.9 M | 43.5 M | - | - |
Cost of Revenue |
413 M | 370 M | 347 M | 322 M | 297 M | 259 M | 212 M | 149 M | 138 M | 134 M | - | - | - | - | - | - | - |
Gross Profit |
314 M | 290 M | 245 M | 188 M | 187 M | 186 M | 197 M | 127 M | 120 M | 110 M | 43.8 M | 40.7 M | 31.7 M | 26.8 M | 19.4 M | 15.8 M | - |
Operating Income |
-116 M | -92.1 M | -108 M | -158 M | -119 M | -14 M | 13 M | 10 M | 2.9 M | 2.16 M | -5.64 M | 2.22 M | 3.17 M | 1.21 M | -409 K | -2.96 M | - |
Interest Expense |
296 K | -379 K | 6.91 M | 7.58 M | 8.22 M | 7.02 M | 3.71 M | 6.23 M | 5.54 M | - | 854 K | 985 K | 989 K | 1.15 M | 768 K | 710 K | - |
EBITDA |
-79.8 M | -53 M | -70.3 M | -122 M | -88.6 M | 11.9 M | 43.3 M | 31.8 M | 26 M | 29.2 M | 1.51 M | 7.86 M | 7.59 M | 5.03 M | 1.68 M | -1.18 M | - |
Operating Expenses |
430 M | 382 M | 352 M | 346 M | 306 M | 200 M | 184 M | 117 M | 117 M | 104 M | 49.4 M | 38.5 M | 28.6 M | 25.6 M | 19.8 M | 18.7 M | - |
General and Administrative Expenses |
273 M | 260 M | 243 M | 243 M | 221 M | 144 M | 128 M | 84.8 M | 88.8 M | 75.8 M | 33.6 M | 23.8 M | 17.4 M | 15.8 M | 12.9 M | 11.3 M | - |
All numbers in USD currency
Quarterly Income Statement NeoGenomics
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
129 M | 129 M | 128 M | 128 M | 127 M | 128 M | 127 M | 126 M | 126 M | 127 M | 126 M | 125 M | 125 M | 127 M | 124 M | 124 M | 124 M | 124 M | 123 M | 118 M | 116 M | 112 M | 110 M | 108 M | 104 M | 104 M | 104 M | 98.3 M | 94.7 M | 93.3 M | 87.3 M | 81 M | 80.5 M | 86.7 M | 79.6 M | 79.4 M | 78.6 M | 78.5 M | 78.1 M | 77.4 M | 76.1 M | 60.9 M | 60.5 M | 60.4 M | 60.3 M | 60 M | 54.4 M | 49.9 M | 49.3 M | 49 M | 48.9 M | 48.8 M | 46.3 M | 45.3 M | 45.2 M | 45 M | 44.7 M | 43.1 M | 43.1 M | 42.9 M | 41.7 M |
Net Income |
-17.1 M | - | -27.1 M | -45.1 M | -25.9 M | - | -17.7 M | -18.6 M | -27.1 M | - | -18.5 M | -24.3 M | -30.8 M | - | -36.9 M | -35.3 M | -49.4 M | - | -20.3 M | 75.9 M | -22.1 M | - | 2.56 M | -6.82 M | -6.98 M | 6.3 M | 2.14 M | 1.99 M | -2.42 M | 353 K | 2.02 M | -380 K | 644 K | 4.55 M | -4.26 M | 483 K | -1.16 M | -6.22 M | -67 K | 413 K | 155 K | -1.47 M | -125 K | -176 K | -761 K | 1.05 M | -291 K | 274 K | 102 K | 857 K | 900 K | 273 K | 3 K | -114 K | -975 K | 551 K | 603 K | 152 K | -143 K | -293 K | -893 K |
Revenue |
187 M | - | 188 M | 181 M | 168 M | - | 168 M | 165 M | 156 M | - | 152 M | 147 M | 137 M | - | 129 M | 125 M | 117 M | - | 121 M | 122 M | 116 M | - | 125 M | 87 M | 106 M | 107 M | 105 M | 102 M | 95.6 M | 76.5 M | 69.1 M | 67.7 M | 63.4 M | 61.4 M | 59.1 M | 62.3 M | 57.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
106 M | - | 107 M | 104 M | 94.8 M | - | 92.9 M | 92 M | 90.8 M | - | 89.6 M | 87 M | 82.4 M | - | 79.9 M | 81.1 M | 78.9 M | - | 74.1 M | 68.7 M | 74 M | - | 71.4 M | 59 M | 59.7 M | - | 53.8 M | 52.7 M | 48.5 M | - | 36.8 M | 37.2 M | 36.1 M | - | 34.2 M | 34.9 M | 34.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
80.9 M | - | 80.4 M | 77.3 M | 73.2 M | - | 74.9 M | 72.5 M | 65.5 M | - | 62.3 M | 59.9 M | 54.8 M | - | 48.9 M | 43.9 M | 38.2 M | - | 47.2 M | 53 M | 41.6 M | - | 54.1 M | 28 M | 46.4 M | 49.9 M | 50.8 M | 49 M | 47.1 M | 37.1 M | 32.3 M | 30.5 M | 27.3 M | 26.8 M | 24.9 M | 27.4 M | 22.9 M | 27.3 M | 27.3 M | 28.6 M | 27.2 M | 12.2 M | 11.2 M | 10.8 M | 9.54 M | 11.5 M | 10.3 M | 10.2 M | 8.71 M | 9.16 M | 8.17 M | 7.16 M | 7.25 M | 6.43 M | 5.89 M | 7.37 M | 7.14 M | 5.83 M | 5.07 M | 4.66 M | 3.86 M |
Operating Income |
-18.2 M | - | -27 M | -47.6 M | -27.8 M | - | -21.2 M | -21.9 M | -30.6 M | - | -24.2 M | -29.9 M | -35.1 M | - | -39.5 M | -39.7 M | -52 M | - | -39.7 M | -22.4 M | -15.1 M | - | 4.67 M | -18.9 M | -5.29 M | - | 3.66 M | 4.48 M | 2.55 M | - | 3.92 M | 794 K | 2.5 M | - | -2.06 M | 1.84 M | -580 K | - | 1.4 M | 2.19 M | 1.92 M | - | 114 K | 28 K | -561 K | - | -73 K | 578 K | 394 K | - | 1.16 M | 505 K | 305 K | - | -684 K | 839 K | 861 K | - | 42 K | -114 K | -711 K |
Interest Expense |
-12 K | - | -335 K | 482 K | 65 K | - | 317 K | -2 K | -263 K | - | -96 K | 730 K | 1.76 M | - | 139 K | 926 K | 168 K | - | 1.3 M | 902 K | 1.18 M | - | 2.46 M | 1.55 M | 819 K | - | 203 K | 1.3 M | 1.83 M | - | 1.87 M | 1.41 M | 1.49 M | - | - | -1.41 M | -1.36 M | - | -1.47 M | -1.45 M | -1.59 M | - | -239 K | -189 K | 195 K | - | - | - | 265 K | - | 231 K | 232 K | 285 K | - | 291 K | 288 K | 258 K | - | 185 K | 179 K | 182 K |
EBITDA |
-9.46 M | - | 295 K | -39.5 M | -18.5 M | - | -12.8 M | -13.6 M | -20.7 M | - | -15.4 M | -21.1 M | -26 M | - | -31 M | -31.2 M | -43.6 M | - | -17.9 M | -8.74 M | -8.43 M | - | 23.4 M | -6.73 M | 947 K | - | 18.9 M | 14.8 M | 7.82 M | - | 15.4 M | 8.24 M | 6.14 M | - | 9.68 M | 9.75 M | 3.4 M | - | 12.9 M | 9.52 M | 5.51 M | - | 5.08 M | 3.28 M | 1.02 M | - | 3.86 M | 2.98 M | 1.54 M | - | 4.28 M | 2.56 M | 1.3 M | - | 1.86 M | 2.44 M | 1.61 M | - | 1.53 M | 849 K | -223 K |
Operating Expenses |
99.1 M | - | 107 M | 125 M | 101 M | - | 96.1 M | 94.4 M | 96 M | - | 86.5 M | 89.8 M | 89.9 M | - | 88.4 M | 83.6 M | 90.3 M | - | 87 M | 75.4 M | 56.7 M | - | 49.4 M | 46.9 M | 51.7 M | - | 47.2 M | 44.5 M | 44.6 M | - | 28.4 M | 29.7 M | 24.8 M | - | 27 M | 25.5 M | 23.5 M | - | 26 M | 26.4 M | 25.3 M | - | 11.1 M | 10.8 M | 10.1 M | - | 10.4 M | 9.66 M | 8.32 M | - | 7.01 M | 6.65 M | 6.94 M | - | 6.58 M | 6.53 M | 6.28 M | - | 5.03 M | 4.77 M | 4.58 M |
General and Administrative Expenses |
65.7 M | - | 69.9 M | 71.7 M | 68.2 M | - | 67 M | 63.3 M | 65.8 M | - | 61.5 M | 60.3 M | 61.5 M | - | 64.3 M | 58 M | 66.2 M | - | 63.8 M | 54.6 M | 40.5 M | - | 36.1 M | 34.6 M | 36.3 M | - | 33.1 M | 29.6 M | 32.1 M | - | 21.1 M | 21 M | 17.1 M | - | 18.3 M | 18.4 M | 17 M | - | 19 M | 18.8 M | 18 M | - | 7.44 M | 7.08 M | 6.52 M | - | 6.37 M | 5.87 M | 5.05 M | - | 4.34 M | 4.06 M | 4.18 M | - | 3.93 M | 4.07 M | 3.75 M | - | 3.18 M | 2.91 M | 2.7 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company NeoGenomics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
CareDx, Inc
CDNA
|
$ 54.31 | 0.32 % | $ 2.89 B |  USA |
 |
Celcuity
CELC
|
$ 79.99 | 0.12 % | $ 3.74 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.88 | 0.09 % | $ 1.01 B | USA |
 |
Danaher Corporation
DHR
|
$ 221.56 | 0.21 % | $ 158 B | USA |
 |
DexCom
DXCM
|
$ 87.73 | 0.21 % | $ 34.2 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 21.27 | 0.51 % | $ 655 M | USA |
 |
Guardant Health
GH
|
$ 176.31 | 0.27 % | $ 22.1 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 163.9 | 0.2 % | $ 12.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 522.02 | 0.1 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
$ 267.86 | 0.41 % | $ 46 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.75 | 3.33 % | $ 89.2 K | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 303.98 | 0.09 % | $ 25.3 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 99.97 | 0.01 % | $ 6.75 B | USA |
 |
Medpace Holdings
MEDP
|
$ 617.15 | 0.23 % | $ 17.8 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 492.34 | 0.11 % | $ 30.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 4.01 | 0.62 % | $ 371 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 6.5 | 4.33 % | $ 5.12 M | USA |
 |
Neogen Corporation
NEOG
|
$ 13.57 | 2.72 % | $ 2.95 B | USA |
 |
Natera
NTRA
|
$ 390.79 | 0.41 % | $ 53.4 B | USA |
 |
Biomerica
BMRA
|
$ 2.61 | 0.36 % | $ 7.61 M | USA |
 |
OPKO Health
OPK
|
$ 1.7 | 0.29 % | $ 1.28 B | USA |
 |
RadNet
RDNT
|
$ 73.21 | 0.11 % | $ 5.5 B | USA |
 |
Sotera Health Company
SHC
|
$ 18.29 | 0.45 % | $ 5.19 B | USA |
 |
Neuronetics
STIM
|
$ 2.88 | 0.21 % | $ 190 M | USA |
 |
Trinity Biotech plc
TRIB
|
$ 7.01 | 0.68 % | $ 2.52 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 158.47 | 0.93 % | $ 9.48 B | USA |
 |
Biodesix
BDSX
|
$ 29.29 | 4.05 % | $ 221 M | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.25 | 2.99 % | $ 31.4 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 420.57 | 0.52 % | $ 25 B | USA |
 |
Exagen
XGN
|
$ 8.55 | 1.39 % | $ 184 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.7 | 0.55 % | $ 9.26 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 15.08 | 11.68 % | $ 162 M |  China |
 |
Bioventus
BVS
|
$ 13.61 | 2.55 % | $ 907 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 13.45 | 0.88 % | $ 457 M | Israel |